Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia.
Drug-induced immune thrombocytopenia (DITP) is a serious complication of drug treatment. Previous studies demonstrated that most drug-dependent antibodies (DDAbs) react with the platelet membrane glycoprotein (GP) complexes IIb/IIIa and Ib/IX/V. We analyzed the sera from 5 patients who presented with DITP after intake of carbimazole. Notably, thrombocytopenia induced by carbimazole was relatively mild in comparison to patients with DITP induced by quinidine. The sera reacted with platelets in an immunoassay on addition of the drug. In immunoprecipitation experiments with biotin-labeled platelets and endothelial cells, reactivity with the platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) could be demonstrated, whereas neither GPIIb/IIIa nor GPIb/IX was precipitated in the presence of the drug. These results could be confirmed by GP-specific immunoassay (MAIPA) using monoclonal antibodies (mabs) against PECAM-1. In addition, the binding of DDAbs could be abolished by preincubation with soluble recombinant PECAM-1. Carbimazole-dependent antibodies showed similar reactivity with platelets carrying the Leu(125) and Val(125) PECAM-1 isoforms, indicating that this polymorphic structure, which is located in the first extracellular domain, is not responsible for the epitope formation. Binding studies with biotin-labeled mutants of PECAM-1 and analysis of sera with mabs against different epitopes on PECAM-1 in MAIPA assay suggested that carbimazole-dependent antibodies prominently bound to the second immunoglobulin homology domain of the molecule. Analysis of 20 sera from patients with quinidine-induced thrombocytopenia by MAIPA assay revealed evidence that DDAbs against PECAM-1 are involved in addition to anti-GPIb/IX and anti-GPIIb/IIIa. We conclude that PECAM-1 is an important target GP in DITP. (Blood. 2000;96:1409-1414)
Kroll
H
H
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University Giessen, Germany. hartmut.e.kroll@immunologie.med.uni-giessen.de
Sun
Q H
QH
Santoso
S
S
D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D000906:Antibodies / Q000097:blood / Q000276:immunology; D013956:Antithyroid Agents / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D002231:Carbimazole / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007118:Immunoassay; D008875:Middle Aged; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000187:drug effects* / Q000276:immunology*; D011802:Quinidine / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000276:immunology
D000889:Anti-Arrhythmia Agents; D000906:Antibodies; D013956:Antithyroid Agents; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D002231:Carbimazole; D011802:Quinidine